These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36188485)

  • 1. The diagnostic accuracy of
    Galvano A; Castellana L; Gristina V; La Mantia M; Insalaco L; Barraco N; Perez A; Cutaia S; Calò V; Bazan Russo TD; Francini E; Incorvaia L; Mirisola MG; Vieni S; Rolfo C; Bazan V; Russo A
    Ther Adv Med Oncol; 2022; 14():17588359221110162. PubMed ID: 36188485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
    Zhou Y; Wang C; Zhu H; Lin Y; Pan B; Zhang X; Huang X; Xu Q; Xu Y; Sun Q
    PLoS One; 2016; 11(6):e0158143. PubMed ID: 27336598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis.
    Galvano A; Taverna S; Badalamenti G; Incorvaia L; Castiglia M; Barraco N; Passiglia F; Fulfaro F; Beretta G; Duro G; Vincenzi B; Tagliaferri P; Bazan V; Russo A
    Ther Adv Med Oncol; 2019; 11():1758835919874653. PubMed ID: 31534493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
    Yang X; Zhang K; Zhang C; Peng R; Sun C
    BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly consistency of
    Liu Y; Li H; Li X; Zhang T; Zhang Y; Zhu J; Cui H; Li R; Cheng Y
    Heliyon; 2024 Jul; 10(13):e34013. PubMed ID: 39071569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of circulating tumor DNA as a minimally invasive biomarker for hepatocellular carcinoma: a systematic review and meta-analysis.
    Li JJ; Lv Y; Ji H
    PeerJ; 2022; 10():e14303. PubMed ID: 36348665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis.
    Zhang Z; Chen P; Xie H; Cao P
    Cancer Med; 2020 Feb; 9(4):1349-1364. PubMed ID: 31876977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.
    Higgins MJ; Jelovac D; Barnathan E; Blair B; Slater S; Powers P; Zorzi J; Jeter SC; Oliver GR; Fetting J; Emens L; Riley C; Stearns V; Diehl F; Angenendt P; Huang P; Cope L; Argani P; Murphy KM; Bachman KE; Greshock J; Wolff AC; Park BH
    Clin Cancer Res; 2012 Jun; 18(12):3462-9. PubMed ID: 22421194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Diagnostic Potentials of Circulating Tumor DNA against Melanoma: A Systematic Review and Meta-Analysis.
    Zhang J; Qian D; Xu X; Xu M; Wang K; Lu H; Shen G
    J Oncol; 2022; 2022():6233904. PubMed ID: 36276290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer.
    Martens GA; Demol J; Dedeurwaerdere F; Breyne J; De Smet K; De Jaeger P; De Smet D
    ESMO Open; 2024 Feb; 9(2):102235. PubMed ID: 38320429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA.
    Zhang R; Chen B; Tong X; Wang Y; Wang C; Jin J; Tian P; Li W
    Cancer Manag Res; 2018; 10():1209-1218. PubMed ID: 29844700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis.
    Passiglia F; Rizzo S; Di Maio M; Galvano A; Badalamenti G; Listì A; Gulotta L; Castiglia M; Fulfaro F; Bazan V; Russo A
    Sci Rep; 2018 Sep; 8(1):13379. PubMed ID: 30190486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.
    Shen H; Che K; Cong L; Dong W; Zhang T; Liu Q; Du J
    Oncotarget; 2017 May; 8(22):36812-36823. PubMed ID: 28415658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic value of circulating tumor DNA in hepatitis B virus induced hepatocellular carcinoma: a systematic review and meta-analysis.
    Chang Y; Jeong SW; Jang JY; Eun H; Lee YS; Song DS; Yu SJ; Lee SH; Kim W; Lee HW; Kim SG; Ryu S; Park S
    J Liver Cancer; 2022 Sep; 22(2):167-177. PubMed ID: 37383408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.
    Dumbrava EE; Call SG; Huang HJ; Stuckett AL; Madwani K; Adat A; Hong DS; Piha-Paul SA; Subbiah V; Karp DD; Fu S; Naing A; Tsimberidou AM; Moulder SL; Koenig KH; Barcenas CH; Kee BK; Fogelman DR; Kopetz ES; Meric-Bernstam F; Janku F
    ESMO Open; 2021 Oct; 6(5):100230. PubMed ID: 34479035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
    Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
    Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer.
    Lyu M; Zhou J; Ning K; Ying B
    Onco Targets Ther; 2019; 12():2539-2552. PubMed ID: 31040697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.